TAVO412

DRUG2 trials

Sponsors

Tavotek Biotherapeutics

Conditions

Cancer

Phase 1

A Study of TAVO412 in Patients with Cancer

Active, not recruitingNCT05548634

Tavotek BiotherapeuticsCancer

Start: 2023-05-08End: 2026-06-01Target: 50Updated: 2024-10-23

A Study of TAVO412 in Patients with Cancer (TAVO412)

RecruitingNCT06761651

Tavotek BiotherapeuticsCancer

Start: 2023-12-20End: 2026-10-15Target: 50Updated: 2025-01-16

Related Papers

Abstract CT050: Preliminary clinical results of TAVO412, an anti-EGFR/cMET/VEGF multispecific antibody, in patients with advanced or metastatic solid tumors

Cancer Research2026-04-17

Abstract CT185: Trispecific EGFR x cMET x VEGF antibody, TAVO412, has clinical responses in esophageal and lung cancers

Cancer Research2025-04-25